Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 29;13(11):1549.
doi: 10.3390/jpm13111549.

Criteria and Non-Criteria Antiphospholipid Antibodies and Cancer in Patients with Involuntary Weight Loss

Simona Caraiola  1   2 , Laura Voicu  2 , Anda Baicus  1   3 , Cristian Baicus  1   2
Affiliations

Criteria and Non-Criteria Antiphospholipid Antibodies and Cancer in Patients with Involuntary Weight Loss

Simona Caraiola et al. J Pers Med. .

Abstract

Cancer patients have higher prevalences of antiphospholipid antibodies (aPLs), occasionally associated with thrombotic events. A cross-sectional study regarding the presence of criteria (IgG/IgM anti-cardiolipin-aCL, anti-β2 glycoprotein I-aβ2GPI) and non-criteria (IgG/IgM anti-phosphatidylserine-aPS, anti-phosphatidylethanolamine-aPE, anti-prothrombin-aPT) aPLs in 146 patients with involuntary weight loss was performed. None of the patients had thrombotic events during the study. Out of the 36 cancer patients, 33 had non-hematologic malignancies. In the cancer subgroup, 60% of the patients had at least one positive aPL, with significantly more patients being positive for aβ2GPI IgG compared with the non-cancer subgroup-p = 0.03, OR = 2.23 (1.02-4.88). When evaluating the titres, aCL IgG/IgM, aβ2GPI IgG, aPE IgG, and aPS IgG had significantly higher values in cancer patients, the best cancer predictor being aβ2GPI IgG-AUC 0.642 (0.542-0.742). Gastrointestinal cancer patients were studied separately, and aCL IgM positivity was significantly higher-p = 0.008, OR = 6.69 (1.35-33.02). Both the titres of aCL IgM (p = 0.006) and aPS IgM (p = 0.03) were higher in the gastrointestinal cancer subgroup, with aCL IgM being the best predictor for gastrointestinal cancer development-AUC 0.808 (0.685-0.932). Despite criteria and non-criteria aPLs being frequent in cancer, their connection with thrombosis in these patients is probably dependent on other important risk factors and needs further research.

Keywords: antiphospholipid antibodies; cancer; involuntary weight loss.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

References

    1. Arreola-Diaz R., Majluf-Cruz A., Sanchez-Torres L.E., Hernandez-Juarez J. The Pathophysiology of the Antiphospholipid Syndrome: A Perspective from the Blood Coagulation System. Clin. Appl. Thromb. Hemost. 2022;28:10760296221088576. doi: 10.1177/10760296221088576. - DOI - PMC - PubMed
    1. Barbhaiya M., Zuily S., Naden R., Hendry A., Manneville F., Amigo M.C., Amoura Z., Andrade D., Andreoli L., Artim-Esen B., et al. 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023;82:1258–1270.
    1. Liu X., Zhu L., Liu H., Cai Q., Yun Z., Sun F., Jia Y., Guo J., Li C. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added. Front. Immunol. 2022;26:972012. doi: 10.3389/fimmu.2022.972012. - DOI - PMC - PubMed
    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Bosch X., Monclús E., Escoda O., Guerra-García M., Moreno P., Guasch N., López-Soto A. Unintentional weight loss: Clinical characteristics and outcomes in a prospective cohort of 2677 patients. PLoS ONE. 2017;12:e0175125. doi: 10.1371/journal.pone.0175125. - DOI - PMC - PubMed